Media stories about Regenxbio (NASDAQ:RGNX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regenxbio earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.691187801342 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
RGNX has been the subject of a number of recent research reports. BidaskClub lowered shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 9th. Raymond James Financial restated a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. Chardan Capital boosted their price target on shares of Regenxbio from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. TheStreet lowered shares of Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. Finally, Zacks Investment Research lowered shares of Regenxbio from a “buy” rating to a “hold” rating in a research note on Friday, November 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $40.63.
Regenxbio (RGNX) traded up $3.10 during midday trading on Wednesday, hitting $32.65. 74,187 shares of the stock traded hands, compared to its average volume of 364,757. Regenxbio has a 12-month low of $16.30 and a 12-month high of $36.45. The company has a market cap of $912.56, a price-to-earnings ratio of -11.48 and a beta of -1.21.
In other news, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $26.56, for a total value of $265,600.00. Following the completion of the sale, the insider now owns 238,530 shares in the company, valued at approximately $6,335,356.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Curran Simpson sold 21,890 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $30.04, for a total transaction of $657,575.60. Following the completion of the sale, the senior vice president now owns 41,390 shares of the company’s stock, valued at approximately $1,243,355.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,890 shares of company stock valued at $2,805,676. Company insiders own 17.00% of the company’s stock.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.